Who
Stephen H. Willard
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Longeveron; Chief Executive Officer, NRX Pharmaceuticals; Director, E Trade Financial.
In numbers
- Trades disclosed
- 36
- Buys
- 2
- Sells
- 0
- Bought
- $158K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 25 May 2006
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $5,1461,987 at $2.59 | filing |
| 1 Jul 2026filed 6 Jul 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $13K18,046 at $0.7291 | filing |
| 1 Jul 2026filed 6 Jul 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $13K18,046 at $0.73 | filing |
| 1 May 2026filed 5 May 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $5,3094,740 at $1.12 | filing |
| 1 Apr 2026filed 3 Apr 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $5,3094,740 at $1.12 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $58K105,533 at $0.545 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN Longeveronoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN Longeveronoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code F | $58K105,533 at $0.55 | filing |
| 2 Mar 2026filed 13 Mar 2026 | LGVN LongeveronBiotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 16 Dec 2022filed 19 Dec 2022 | NRXP NRX PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $59K50,000 at $1.17 | filing |
| 9 May 2013filed 13 May 2013 | E Trade Financial | SEC FORM 4 Code A | —4,575 at $0.00 | filing |
| 10 May 2012filed 14 May 2012 | E Trade Financial | SEC FORM 4 Code A | —5,154 at $0.00 | filing |
| 12 May 2011filed 16 May 2011 | E Trade Financial | SEC FORM 4 Code A | —3,086 at $0.00 | filing |
| 13 May 2010filed 17 May 2010 | E Trade Financial | SEC FORM 4 Code A | —30,959 at $0.00 | filing |
News
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free KetamineNRXP · manilatimes.net · 19 Oct 2026NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineNRXP · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Stephen H. Willard; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.